Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Allobaculum is a genus of Gram-positive, non-spore-forming, strictly anaerobic, and non-motile bacteria in the family Erysipelotrichidae[1]. The genus includes species like Allobaculum stercoricanis, Allobaculum mucolyticum, and Allobaculum fili, some of which are part of the normal mammalian, including human, gut microbiota[1][3][5]. Certain species, particularly Allobaculum mucolyticum, possess a broad repertoire of carbohydrate-active enzymes (CAZymes) that degrade intestinal mucin O-glycans, aiding in colonization of the mucosal niche[2][3][5][7]. While some Allobaculum are associated with health benefits such as butyrate production, others—especially newly described species in humans—are implicated in potentially pathogenic mucus layer erosion, immune modulation, and may contribute to inflammatory bowel disease pathogenesis when overabundant or misregulated[3][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Allobaculum (Genus).